SCHEMBL25233992

SCHEMBL25233992

CCOC(=O)c1cc2cc(F)c(COC)cc2n1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.40
KDM4E B2RXH2 7/20 0.40
TSHR P16473 2/20 0.40
HSD17B10 Q99714 2/20 0.40
GAA P10253 2/20 0.40
CRHBP P24387 1/20 0.40
CRHR2 Q13324 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
RECQL P46063 1/20 0.39
NOD2 Q9HC29 3/20 0.39
NOD1 Q9Y239 3/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
NPSR1 Q6W5P4 1/20 0.38
ALDH1A1 P00352 4/20 0.38
MAPK1 P28482 2/20 0.38
LMNA P02545 1/20 0.36
MAOA P21397 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30193976 0.81 MAPT (0.42) MAPTKDM4EHSD17B10CRHBPCRHR2
SCHEMBL19331988 0.81 MAPT (0.42) MAPTKDM4EHSD17B10CRHBPCRHR2
SCHEMBL26688531 0.78 NOD2 (0.62) MAPTKDM4ETSHRGAACRHBP
SCHEMBL19331980 0.78 MAPT (0.42) MAPTKDM4EHSD17B10CRHBPCRHR2
SCHEMBL29189066 0.77 NOD2 (0.51) MAPTKDM4ETSHRHSD17B10GAA
SCHEMBL30436082 0.77 NOD2 (0.46) MAPTKDM4ETSHRGAACRHBP
SCHEMBL29189067 0.77 NOD2 (0.46) MAPTKDM4ETSHRGAACRHBP
SCHEMBL23441048 0.76 KDM4E (0.46) MAPTKDM4ETSHRHSD17B10GAA
SCHEMBL31412989 0.76 SRD5A1 (0.53) MAPTKDM4EHSD17B10CRHBPCRHR2
SCHEMBL3920560 0.75 NOD2 (0.53) MAPTKDM4ETSHRHSD17B10GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230374017-A1 COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2023-11-23 US disclosed
US-20230374017-A1 COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2023-11-23 US disclosed
US-20230374017-A1 COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2023-11-23 US disclosed
CN-116249531-A Compositions and methods for activating pyruvate kinase 密执安大学评议会 2023-06-09 CN disclosed
EP-4185293-A1 COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE The Regents of The University of Michigan (US) 2023-05-31 EP disclosed
WO-2022020424-A1 COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2022-01-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230374017-A1 COMPOSITIONS AND METHODS FOR ACTIVATING PYRUVATE KINASE PCK1, PDK2, PDK1 MAPT 2067/4885KDM4E 1883/4885TSHR 3270/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.